We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01818804
Recruitment Status : Completed
First Posted : March 27, 2013
Results First Posted : June 9, 2020
Last Update Posted : June 9, 2020
Information provided by (Responsible Party):
Salome Kristensen, Aalborg University Hospital

Brief Summary:

Background: There is evidence for a high cardiovascular risk in rheumatic and inflammatory diseases . Recent evidence suggest that psoriatic arthritis is also associated with an increased cardiovascular risk with accelerated atherosclerosis and increased cardiovascular risk. However, data regarding cardiovascular comorbidity and cardiovascular risk factors in patients with psoriatic arthritis are limited.

Objective: The aim of this study is to investigate the effect of daily supplementation with 3 g n-3 polyunsaturated fatty acids on risk markers for cardiovascular disease and inflammation in patients with psoriatic arthritis.

Design: Randomized double-blind, placebo-controlled, multicenter trial with n-3 polyunsaturated fatty acids in patient with psoriatic arthritis.

Setting: Departments of Rheumatology, Nephrology and Cardiology at Aalborg University Hospital and Vendsyssel Hospital in Region Northern Denmark

Participants: 156 men and women aged > 18 years with psoriatic arthritis classified by the CASPAR criteria will be included. Exclusion criteria: cardiac arrhythmias, conduction disturbances, treatment with biological drugs or oral corticosteroids. Inclusion time: spring 2013 to spring 2015.

Method: The following data will be collected for each participant: Interview including dietary records, assessment of tender and swollen joints, enthesitis, dactylitis, patient global assessment of disease activity (Visual Analogue Scale ), global assessment of pain (Visual Analogue Scale), psoriatic skin involvement by Psoriatic Area and Severity Index (PASI), laboratory parameters of disease activity and risk markers of cardiovascular disease.

For detection of early cardiovascular risk markers Heart Rate Variability (HRV) and Pulse Wave Velocity (PWV) will be performed.

Main outcome measures: The primary endpoint will be HRV and secondary endpoints will be PWV, inflammatory activity and use of analgesics.

The trial is approved by The local Ethics Committee, registration number N20120076

Condition or disease Intervention/treatment Phase
Psoriatic Arthritis Dietary Supplement: n-3PUFA Dietary Supplement: olive oil Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 145 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effect of n-3 Polyunsaturated Fatty Acids on Risk Markers for Cardiovascular Disease and Inflammation in Patients With Psoriatic Arthritis
Study Start Date : March 2013
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Arm Intervention/treatment
Active Comparator: n-3PUFA
n-3 polyunsaturated fattyacids from fish oil
Dietary Supplement: n-3PUFA
Other Name: n-3 polyunsaturated fattyacids from fishoil

Placebo Comparator: olive oil
Olive oil
Dietary Supplement: olive oil

Primary Outcome Measures :
  1. Change in Heart Rate Variability (HRV) Measure [ Time Frame: 24 week ]
    Heart Rate variability, non-invasive measurement for the autonom regulation of the heart associated with risk of cardiovascular disease

Secondary Outcome Measures :
  1. Change in PWV [ Time Frame: 24 weeks ]
    Pulse wave Velocity, non-invasive measurement for arterioscleroses

Other Outcome Measures:
  1. Change in Disease Activity [ Time Frame: 24 weeks ]

    Disease activity score (DAS-28) is a system developed and validated by the EULAR (European League Against Rheumatism) to measure the progress and improvement of Rheumatoid Arthritis. DAS28 is often used in clinical trials for arthritis

    DAS28 values range from 2.0 to 10.0 while higher values mean a higher disease activity. A DAS 28 below the value of 2.6 is interpreted as Remission.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women aged > 18 years with
  • Psoriatic arthritis classified by the CASPAR criteria
  • written informed consent

Exclusion Criteria:

  • Treatment with biological drugs
  • Treatment with oral corticosteroids
  • cardiac arrhythmias

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01818804

Layout table for location information
Aalborg University Hospital, Department of Rheumatology
Aalborg, Denmark, 9000
Vendsyssel Hospital in Region Northern Denmark, Department of Rheumatology
Hjørring, Denmark, 9800
Sponsors and Collaborators
Aalborg University Hospital
Layout table for investigator information
Principal Investigator: Salome Kristensen, MD Aalborg Universityhospital, Department og Rheumatology
Study Director: Jeppe H Christensen, Professor Aalborg University Hospital, Department of Nephrology
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Salome Kristensen, MD, Aalborg University Hospital
ClinicalTrials.gov Identifier: NCT01818804    
Other Study ID Numbers: N-20120076
First Posted: March 27, 2013    Key Record Dates
Results First Posted: June 9, 2020
Last Update Posted: June 9, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spinal Diseases
Bone Diseases
Skin Diseases, Papulosquamous
Skin Diseases